JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Danaher Corp

Cerrado

SectorSalud

223.58 0.49

Resumen

Variación precio

24h

Actual

Mínimo

223.09

Máximo

223.98

Métricas clave

By Trading Economics

Ingresos

-399M

555M

Ventas

195M

5.9B

P/B

Media del Sector

44.433

37.461

BPA

0.77

Rentabilidad por dividendo

0.56

Margen de beneficio

9.35

Empleados

61,000

EBITDA

-455M

1.3B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+9.17% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.56%

2.33%

Fecha Próximo Dividendo

31 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

15B

150B

Apertura anterior

223.09

Cierre anterior

223.58

Noticias sobre sentimiento de mercado

By Acuity

39%

61%

111 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Danaher Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 oct 2025, 17:41 UTC

Ganancias

Danaher 3Q Earnings Rise; Pharma R&D Spend Expected to Rebound -- Update

21 oct 2025, 10:28 UTC

Ganancias

Danaher 3Q Sales and Profit Rise on Bioprocessing Momentum

22 jul 2025, 11:32 UTC

Ganancias

Danaher Posts Lower 2Q Profit, Names Next CFO -- Update

22 jul 2025, 10:42 UTC

Ganancias

Danaher Posts Higher 2Q Sales, Lower Profit

22 abr 2025, 10:34 UTC

Ganancias

Danaher 1Q Results Decline But Top Estimates

21 oct 2025, 10:02 UTC

Ganancias

Danaher 3Q Adjusted Core Revenue Rose 3% >DHR

21 oct 2025, 10:01 UTC

Ganancias

Danaher Sees 2025 Adjusted Core Revenue Up Low-Single Digits >DHR

21 oct 2025, 10:01 UTC

Ganancias

Danaher Backs 2025 View of Adj EPS $7.70-Adj EPS $7.80 >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Operating Cash Flow $1.7B, Free Cash Flow $1.4B >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Net $908M >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Sales $6.05B >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q Adj EPS $1.89 >DHR

21 oct 2025, 10:00 UTC

Ganancias

Danaher 3Q EPS $1.27 >DHR

22 jul 2025, 10:03 UTC

Ganancias

Danaher Had Seen 2025 Adjusted EPS $7.60-$7.75 >DHR

22 jul 2025, 10:03 UTC

Ganancias

Danaher Raises 2025 View To Adj EPS $7.70-Adj EPS $7.80 >DHR

22 jul 2025, 10:02 UTC

Ganancias

Danaher Still Sees 2025 Core Revenue Up About 3% >DHR

22 jul 2025, 10:01 UTC

Ganancias

Danaher Sees 3Q Core Revenue Up Low-Single Digits >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Operating Cash Flow $1.3B, Free Cash Flow $1.1B >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Net $555M >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Sales $5.9B >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q Adj EPS $1.80 >DHR

22 jul 2025, 10:00 UTC

Ganancias

Danaher 2Q EPS 77c >DHR

22 jul 2025, 09:34 UTC

Acciones populares

Stocks to Watch Tuesday: Coca-Cola, GM, AstraZeneca, NXP -- WSJ

14 jul 2025, 16:12 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

22 abr 2025, 10:02 UTC

Ganancias

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 abr 2025, 10:02 UTC

Ganancias

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 abr 2025, 10:02 UTC

Ganancias

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 abr 2025, 10:01 UTC

Ganancias

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 abr 2025, 10:01 UTC

Ganancias

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 abr 2025, 10:00 UTC

Ganancias

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

Comparación entre iguales

Cambio de precio

Danaher Corp Esperado

Precio Objetivo

By TipRanks

9.17% repunte

Estimación a 12 meses

Media 243.45 USD  9.17%

Máximo 260 USD

Mínimo 220 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Danaher Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

11

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

189.8851 / 196.5Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

111 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
help-icon Live chat